We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $14 · 3 analysts
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Stored first · Google News · Yahoo Finance (English)
Curis Lifesciences FY26 net profit rises 11.4% to ₹691.63 lakh - scanx.trade
Curis Lifesciences FY26 net profit rises 11.4% to ₹691.63 lakh scanx.trade
Ilan Curis - Transfermarkt
Ilan Curis Transfermarkt
Curis (NASDAQ: CRIS) wins shareholder approval to double authorized common stock - Stock Titan
Curis (NASDAQ: CRIS) wins shareholder approval to double authorized common stock Stock Titan
CRIS News | CURIS INC (NASDAQ:CRIS) - ChartMill
CRIS News | CURIS INC (NASDAQ:CRIS) ChartMill
Curis stock (US2312691006): Phase 1 data update lifts attention - AD HOC NEWS
Curis stock (US2312691006): Phase 1 data update lifts attention AD HOC NEWS
Curis stock (US2312691006): cancer drug setback keeps investors on edge - AD HOC NEWS
Curis stock (US2312691006): cancer drug setback keeps investors on edge AD HOC NEWS
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 11. | After market close (AMC) | $-0.35 | — | — | $750K | — | Scheduled |
| FY2026 Q1 | 2025. 03. 31. | Time TBD | — | $-1.25 | — | — | $2.38M | Reported |
| FY2025 Q3 | 2024. 09. 30. | Time TBD | — | $-5.77 | — | — | $7.56M | Reported |
| FY2025 Q2 | 2024. 06. 30. | Time TBD | — | $-4.08 | — | — | $4.63M | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 03. 20. | HC Wainwright & Co. | — | Maintain | Buy → Buy | — | HC Wainwright & Co.: Buy |
| 2025. 04. 01. | HC Wainwright & Co. | — | Maintain | Buy → Buy | — | HC Wainwright & Co.: Buy |
Compare a firm's past rating changes and its actions on other stocks in the same sector.
As of FY2026Q1 · Source: SEC/DART + price data
Filings, earnings, and institutional changes summarized in one paragraph, with source links.
No holdings data to show.
See new positions, full exits, and weight changes.